Heterogeneous expression of E-cadherin and p53 in prostate cancer: Clinical implications

Emiel Ruijter; Christina Van De Kaa; Tilly Aalders; Dirk Ruiter; Gary Miller; Frans Debruyne; Jack Schalken; F. H. Schröder; C. G.M. Beeker; B. G. Blijenberg; A. E. Boeken Kruger; I. Eman; R. F. Hoedemaeker; W. J. Kirkels; R. Kranse; Th H. Van Der Kwast; M. A. Noordzij; H. J.A. Van De Poel; J. C. Romijn; G. J. Van Steenbrugge; J. Trapman; N. S. Verkaik; M. J.G. Bussemakers; D. Hessels; G. O.N. Oosterhof; T. E.G. Ruijter; J. A. Schalken; C. M.G. Thomas; J. A. Witjes; A. Ylikoski; T. Lövgren; J. Lövgren; K. Pettersson; T. Piironen; S. Mansikka-Savolainen; G. Ahlgren; C. Beeker; A. Bjartell; T. Björk; H. Lilja; A. Lundwall; P. A. Abrahamsson; O. Bratt; S. Colleen; P. Elfring; H. Frederiksen; S. Mårtensson; F. C. Hamdy; H. Y. Leung; D. E. Neal; C. N. Robson

Heterogeneous expression of E-cadherin and p53 in prostate cancer: Clinical implications

Emiel Ruijter, Christina Van De Kaa, Tilly Aalders, Dirk Ruiter, Gary Miller, Frans Debruyne, Jack Schalken, F. H. Schröder, C. G.M. Beeker, B. G. Blijenberg, A. E. Boeken Kruger, I. Eman, R. F. Hoedemaeker, W. J. Kirkels, R. Kranse, Th H. Van Der Kwast, M. A. Noordzij, H. J.A. Van De Poel, J. C. Romijn, G. J. Van SteenbruggeJ. Trapman, N. S. Verkaik, M. J.G. Bussemakers, D. Hessels, G. O.N. Oosterhof, T. E.G. Ruijter, J. A. Schalken, C. M.G. Thomas, J. A. Witjes, A. Ylikoski, T. Lövgren, J. Lövgren, K. Pettersson, T. Piironen, S. Mansikka-Savolainen, G. Ahlgren, C. Beeker, A. Bjartell, T. Björk, H. Lilja, A. Lundwall, P. A. Abrahamsson, O. Bratt, S. Colleen, P. Elfring, H. Frederiksen, S. Mårtensson, F. C. Hamdy, H. Y. Leung, D. E. Neal, C. N. Robson

Research Collaboration Unit

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Abstract

Histologic grade and rumor volume are markers of malignant phenotype. More objective markers, however, have been sought for needle biopsy specimens. The aim of this study was to evaluate how immunohistochemical expression of the potential prognostic markers E-cadherin and p53 in biopsy specimens relates to the expression of these markers in prostatectomy specimens. Therefore, we analyzed 47 prostatectomy specimens and their pre operative biopsy specimens. Fixation of surgical specimens and the immunohistochemical assay for both E-cadherin and p53 expression was optimized. All paraffin blocks containing areas of carcinoma were submitted for immunohistochemical analysis. The prevalence of abnormal p53 immunoreactivity was only 11%. In addition, abnormal p53 expression was virtually restricted to cases that were already identified as having a poor prognosis on the basis of the large volume and the high grade of their carcinomas. In 28% of the cases, we found abnormal immunoreactivity for E- cadherin. These cases revealed considerable heterogeneity in topographic distribution of abnormal expression. The level of sensitivity to the detection of abnormal E-cadherin expression or abnormal p53 in the prostatectomy specimen was 15% and 60%, respectively. In view of the inherent heterogeneity of E-cadherin expression and the low prevalence of abnormal p53 expression, we question the use of these markers for prognostic purposes in needle biopsy specimens. Unless representative sampling by needle biopsy can be assured, the use of E-cadherin expression will be of most value in prostatectomy specimens.

Original language	English
Pages (from-to)	276-281
Number of pages	6
Journal	Modern Pathology
Volume	11
Issue number	3
State	Published - Mar 1998

Keywords

E-cadherin
Heterogeneity
p53
Prostate biopsy
Prostatectomy

Cite this

Ruijter, E., Van De Kaa, C., Aalders, T., Ruiter, D., Miller, G., Debruyne, F., Schalken, J., Schröder, F. H., Beeker, C. G. M., Blijenberg, B. G., Boeken Kruger, A. E., Eman, I., Hoedemaeker, R. F., Kirkels, W. J., Kranse, R., Van Der Kwast, T. H., Noordzij, M. A., Van De Poel, H. J. A., Romijn, J. C., ... Robson, C. N. (1998). Heterogeneous expression of E-cadherin and p53 in prostate cancer: Clinical implications. Modern Pathology, 11(3), 276-281.

@article{6fc7ec3759084e48a4179fd4e2bc0e7a,

title = "Heterogeneous expression of E-cadherin and p53 in prostate cancer: Clinical implications",

abstract = "Histologic grade and rumor volume are markers of malignant phenotype. More objective markers, however, have been sought for needle biopsy specimens. The aim of this study was to evaluate how immunohistochemical expression of the potential prognostic markers E-cadherin and p53 in biopsy specimens relates to the expression of these markers in prostatectomy specimens. Therefore, we analyzed 47 prostatectomy specimens and their pre operative biopsy specimens. Fixation of surgical specimens and the immunohistochemical assay for both E-cadherin and p53 expression was optimized. All paraffin blocks containing areas of carcinoma were submitted for immunohistochemical analysis. The prevalence of abnormal p53 immunoreactivity was only 11\%. In addition, abnormal p53 expression was virtually restricted to cases that were already identified as having a poor prognosis on the basis of the large volume and the high grade of their carcinomas. In 28\% of the cases, we found abnormal immunoreactivity for E- cadherin. These cases revealed considerable heterogeneity in topographic distribution of abnormal expression. The level of sensitivity to the detection of abnormal E-cadherin expression or abnormal p53 in the prostatectomy specimen was 15\% and 60\%, respectively. In view of the inherent heterogeneity of E-cadherin expression and the low prevalence of abnormal p53 expression, we question the use of these markers for prognostic purposes in needle biopsy specimens. Unless representative sampling by needle biopsy can be assured, the use of E-cadherin expression will be of most value in prostatectomy specimens.",

keywords = "E-cadherin, Heterogeneity, p53, Prostate biopsy, Prostatectomy",

author = "Emiel Ruijter and \{Van De Kaa\}, Christina and Tilly Aalders and Dirk Ruiter and Gary Miller and Frans Debruyne and Jack Schalken and Schr{\"o}der, \{F. H.\} and Beeker, \{C. G.M.\} and Blijenberg, \{B. G.\} and \{Boeken Kruger\}, \{A. E.\} and I. Eman and Hoedemaeker, \{R. F.\} and Kirkels, \{W. J.\} and R. Kranse and \{Van Der Kwast\}, \{Th H.\} and Noordzij, \{M. A.\} and \{Van De Poel\}, \{H. J.A.\} and Romijn, \{J. C.\} and \{Van Steenbrugge\}, \{G. J.\} and J. Trapman and Verkaik, \{N. S.\} and Bussemakers, \{M. J.G.\} and D. Hessels and Oosterhof, \{G. O.N.\} and Ruijter, \{T. E.G.\} and Schalken, \{J. A.\} and Thomas, \{C. M.G.\} and Witjes, \{J. A.\} and A. Ylikoski and T. L{\"o}vgren and J. L{\"o}vgren and K. Pettersson and T. Piironen and S. Mansikka-Savolainen and G. Ahlgren and C. Beeker and A. Bjartell and T. Bj{\"o}rk and H. Lilja and A. Lundwall and Abrahamsson, \{P. A.\} and O. Bratt and S. Colleen and P. Elfring and H. Frederiksen and S. M{\aa}rtensson and Hamdy, \{F. C.\} and Leung, \{H. Y.\} and Neal, \{D. E.\} and Robson, \{C. N.\}",

year = "1998",

month = mar,

language = "Ingl{\'e}s",

volume = "11",

pages = "276--281",

journal = "Modern Pathology",

issn = "0893-3952",

publisher = "Nature Publishing Group",

number = "3",

}

Ruijter, E, Van De Kaa, C, Aalders, T, Ruiter, D, Miller, G, Debruyne, F, Schalken, J, Schröder, FH, Beeker, CGM, Blijenberg, BG, Boeken Kruger, AE, Eman, I, Hoedemaeker, RF, Kirkels, WJ, Kranse, R, Van Der Kwast, TH, Noordzij, MA, Van De Poel, HJA, Romijn, JC, Van Steenbrugge, GJ, Trapman, J, Verkaik, NS, Bussemakers, MJG, Hessels, D, Oosterhof, GON, Ruijter, TEG, Schalken, JA, Thomas, CMG, Witjes, JA, Ylikoski, A, Lövgren, T, Lövgren, J, Pettersson, K, Piironen, T, Mansikka-Savolainen, S, Ahlgren, G, Beeker, C, Bjartell, A, Björk, T, Lilja, H, Lundwall, A, Abrahamsson, PA, Bratt, O, Colleen, S, Elfring, P, Frederiksen, H, Mårtensson, S, Hamdy, FC, Leung, HY, Neal, DE & Robson, CN 1998, 'Heterogeneous expression of E-cadherin and p53 in prostate cancer: Clinical implications', Modern Pathology, vol. 11, no. 3, pp. 276-281.

TY - JOUR

T1 - Heterogeneous expression of E-cadherin and p53 in prostate cancer

T2 - Clinical implications

AU - Ruijter, Emiel

AU - Van De Kaa, Christina

AU - Aalders, Tilly

AU - Ruiter, Dirk

AU - Miller, Gary

AU - Debruyne, Frans

AU - Schalken, Jack

AU - Schröder, F. H.

AU - Beeker, C. G.M.

AU - Blijenberg, B. G.

AU - Boeken Kruger, A. E.

AU - Eman, I.

AU - Hoedemaeker, R. F.

AU - Kirkels, W. J.

AU - Kranse, R.

AU - Van Der Kwast, Th H.

AU - Noordzij, M. A.

AU - Van De Poel, H. J.A.

AU - Romijn, J. C.

AU - Van Steenbrugge, G. J.

AU - Trapman, J.

AU - Verkaik, N. S.

AU - Bussemakers, M. J.G.

AU - Hessels, D.

AU - Oosterhof, G. O.N.

AU - Ruijter, T. E.G.

AU - Schalken, J. A.

AU - Thomas, C. M.G.

AU - Witjes, J. A.

AU - Ylikoski, A.

AU - Lövgren, T.

AU - Lövgren, J.

AU - Pettersson, K.

AU - Piironen, T.

AU - Mansikka-Savolainen, S.

AU - Ahlgren, G.

AU - Beeker, C.

AU - Bjartell, A.

AU - Björk, T.

AU - Lilja, H.

AU - Lundwall, A.

AU - Abrahamsson, P. A.

AU - Bratt, O.

AU - Colleen, S.

AU - Elfring, P.

AU - Frederiksen, H.

AU - Mårtensson, S.

AU - Hamdy, F. C.

AU - Leung, H. Y.

AU - Neal, D. E.

AU - Robson, C. N.

PY - 1998/3

Y1 - 1998/3

N2 - Histologic grade and rumor volume are markers of malignant phenotype. More objective markers, however, have been sought for needle biopsy specimens. The aim of this study was to evaluate how immunohistochemical expression of the potential prognostic markers E-cadherin and p53 in biopsy specimens relates to the expression of these markers in prostatectomy specimens. Therefore, we analyzed 47 prostatectomy specimens and their pre operative biopsy specimens. Fixation of surgical specimens and the immunohistochemical assay for both E-cadherin and p53 expression was optimized. All paraffin blocks containing areas of carcinoma were submitted for immunohistochemical analysis. The prevalence of abnormal p53 immunoreactivity was only 11%. In addition, abnormal p53 expression was virtually restricted to cases that were already identified as having a poor prognosis on the basis of the large volume and the high grade of their carcinomas. In 28% of the cases, we found abnormal immunoreactivity for E- cadherin. These cases revealed considerable heterogeneity in topographic distribution of abnormal expression. The level of sensitivity to the detection of abnormal E-cadherin expression or abnormal p53 in the prostatectomy specimen was 15% and 60%, respectively. In view of the inherent heterogeneity of E-cadherin expression and the low prevalence of abnormal p53 expression, we question the use of these markers for prognostic purposes in needle biopsy specimens. Unless representative sampling by needle biopsy can be assured, the use of E-cadherin expression will be of most value in prostatectomy specimens.

AB - Histologic grade and rumor volume are markers of malignant phenotype. More objective markers, however, have been sought for needle biopsy specimens. The aim of this study was to evaluate how immunohistochemical expression of the potential prognostic markers E-cadherin and p53 in biopsy specimens relates to the expression of these markers in prostatectomy specimens. Therefore, we analyzed 47 prostatectomy specimens and their pre operative biopsy specimens. Fixation of surgical specimens and the immunohistochemical assay for both E-cadherin and p53 expression was optimized. All paraffin blocks containing areas of carcinoma were submitted for immunohistochemical analysis. The prevalence of abnormal p53 immunoreactivity was only 11%. In addition, abnormal p53 expression was virtually restricted to cases that were already identified as having a poor prognosis on the basis of the large volume and the high grade of their carcinomas. In 28% of the cases, we found abnormal immunoreactivity for E- cadherin. These cases revealed considerable heterogeneity in topographic distribution of abnormal expression. The level of sensitivity to the detection of abnormal E-cadherin expression or abnormal p53 in the prostatectomy specimen was 15% and 60%, respectively. In view of the inherent heterogeneity of E-cadherin expression and the low prevalence of abnormal p53 expression, we question the use of these markers for prognostic purposes in needle biopsy specimens. Unless representative sampling by needle biopsy can be assured, the use of E-cadherin expression will be of most value in prostatectomy specimens.

KW - E-cadherin

KW - Heterogeneity

KW - p53

KW - Prostate biopsy

KW - Prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=0031914109&partnerID=8YFLogxK

M3 - Artículo

C2 - 9521475

AN - SCOPUS:0031914109

SN - 0893-3952

VL - 11

SP - 276

EP - 281

JO - Modern Pathology

JF - Modern Pathology

IS - 3

ER -

Heterogeneous expression of E-cadherin and p53 in prostate cancer: Clinical implications

Abstract

Keywords

Other files and links

Fingerprint

Cite this